Experimental approach | Molecular characteristics of PCSCs | References |
---|---|---|
Isolated SP(side population) cell fractions in L3.6pl cell‚ gemcitabine- and 5-FU-resistant L3.6pl cells were established | Induce faster and more aggressive orthotopic tumor growth with higher rates of metastases‚ gemcitabine resulted in an increase of CD24 positive cells and the percentage of SP cells | [117] |
Incubated in the presence of 5- fluorouracil (5-FU) for 24Â h, and further incubated without 5-FU for 28Â days to eliminate 5-FU-sensitive cells. | Certain stemness-genes such as OCT4 and NANOG were enhanced and spheres arose | [118] |
Treat Capan-1 and Panc-1 cells with serial concentrations of gemcitabine and counting surviving cells after 6Â days, | Stem markers CD44,CD24,CD133,EpCAM,Oct4 and PDX1 increased | [119] |
Xenograft tumours were dissociated into single cells and identified SP cells using FACS analysis | SP displayed higher sphere-forming capacity, epithelial-mesenchymal transition and gemcitabine reisistant | [120] |
Konckdown of ALDH1 in MIA PaCa-2 cell | The IC50 of gemcitabine decreased, induction of apoptosis and S-phase arrest by gemcitabine. | [121] |
Enriched pancreatic cancer stem CD44+/CD24+ cells in PANC-1 cells under sphere forming conditions | Increased resistance to gemcitabine, migration ability, exhibit Epithelial to Mesenchymal Transition (EMT) | [122] |